Articles mentioning Bristol-Myers Squibb Co. (BMY)

Results 11 - 20 of 758 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for BMY

Investing | January 10, 2015

Can You Guess the Most Common Reason People Visit the Doctor?

The most common reason people visit their doctor, according to a study from the Mayo Clinic, may surprise you.

Investing | December 24, 2014

This Cancer Drug War Is Just Getting Started

The FDA approves Bristol-Myers Squibb's Opdivo, pitting it against Merck's Keytruda that was approved earlier this year.

Investing | December 19, 2014

3 Pharma Giants Growing Significantly Faster Than Pfizer, Inc.

Pfizer is a staple in most retirement and income portfolios, but investors can find stronger growth prospects in each of these three big pharmaceutical stocks.

Investing | December 06, 2014

Is Obamacare Failing Where It's Needed Most?

A recent study shows that while Obamacare has dramatically reduced the number of uninsured, it's failing to provide a boost in this important area which is vital to Obamacare's long-term success.

Investing | December 01, 2014

Bristol-Myers Squibb and Pfizer Inc.'s Bet on This Small Biotech Stock Could Pay Off

Sales of Bristol-Myers Squibb and Pfizer's Eliquis could grow if Portola Pharmaceuticals' andexanet alfa eventually gets FDA approval.

Investing | November 29, 2014

Bristol-Myers Squibb Co's Hep C Drug Denied; Gilead Sciences Inc. Smiling (for Now)

The FDA rejected daclatasvir, but Bristol-Myers Squibb still has plans for the hepatitis C drug.

Investing | November 24, 2014

Why These Big Pharma Stocks Could Plunge Next Year

We asked three of our top healthcare analysts which big pharma stocks could face tough times in 2015. Here is what they had to say.

Investing | November 20, 2014

Will Bristol-Myers Squibb's Dividend Be Safe?

Bristol-Myers Squibb is battling patent expiration, but some fast-growing new drugs just may be able to save its dividend.

Investing | November 10, 2014

3 Drugs That Make Gilead Sciences' Harvoni Look Cheap

Cancer drugs from Bristol-Myers Squibb, Novartis, and Roche come with higher price tags than Gilead Sciences hepatitis C drug Harvoni.

Investing | November 05, 2014

Why Bristol-Myers Squibb Co. Leaped 15% Higher in October

Bristol-Myers Squibb was among the best performing pharmaceutical stocks in October, launching 15% higher and tacking on more than $12 billion in market value. Find out what sent Bristol-Myers' shares soaring higher and whether or not it'll continue.

Results 11 - 20 of 758 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for BMY


Advertisement